Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4287-4291

  Duns, Gerben ^a   Van Berg, Eva Den ^a   Van Duivenbode, Inge ^a   Osinga, Jan ^a   Hollema, Harry ^a   Hofstra, Robert M W ^a   Kok, Klaas ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE METHYLTRANSFERASE; MESSENGER RNA;

ARTICLE; CARCINOMA CELL; CHROMOSOME 3P; CONTROLLED STUDY; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; METHYLATION; MISSENSE MUTATION; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; SETD2 GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER;

EID: 77953170322     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0120     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-823
3. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
4. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-4734
5. Van den Berg A, Dijkhuizen T, Draaijers TG, et al. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer 1997;19:59-76.
6. Noensie EN, Dietz HC. A strategy for disease gene identification through nonsense mediated mRNA decay inhibition. Nat Biotechnol 2001;19:434-439
7. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense decay identifies gene mutations in colon cancer cells with microsatellite instability. Oncogene 2004;23: 639-645
8. Huusko P, Poncinano-Jackson D, Wolf M, et al. Nonsense-mediated decay microarray analysis identifies mutation of EPHB2 in human prostate cancer. Nat Genet 2004;36:979-983
9. Muggerud AA, Edgren H, Wolf M, et al. Data integration from two microarray platforms identifies bi-allelic inactivation of RIC8A in a breast cancer cell line. BMC Med Genet 2009;2:26-34.
10. Du P, Jibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;59:1547-1548
11. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for llumina microarray data. Nucleic Acids Res 2008; 36:e11.
12. Bardelli A, Parsons D, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
13. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying enzymes. Nature 2010;463:360-363
14. Kok K, Osinga J, Carritt B, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987;330:578-581
15. + hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proc Natl Acad Sci U S A 1998;95:8175-8180
16. Rega S, Stiewe T, Chang D-I, et al. Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA binding factor. Moll Cell Neurosci 2001;18:68-79.
17. Miremadi A, Oestergaard MZ, Pharoah PDP, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007;16:Spec No. 1:R28-49.
18. El Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer 2009;9:290-296
19. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/SETD mediates all H3K36 trimethylation. EMBO J 2008;27:406-420
20. Yoh SM, Lucas JS, Jones KA. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYP/Setd2-mediated histone H3K36 methylation. Gene Dev 2008;22:3422-3434
21. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet 2009;41:376-381